Label: PLASMA-LYTE 148- sodium chloride, sodium gluconate, sodium acetate, potassium chloride, and magnesium chloride injection, solution

  • NDC Code(s): 0338-0179-03, 0338-0179-04
  • Packager: Baxter Healthcare Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL

Drug Label Information

Updated August 5, 2019

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

View All Sections
  • DESCRIPTION

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with hydrochloric acid. The pH is 5.5 (4.0 to 8.0).

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 140 mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate, and 23 mEq gluconate. The osmolarity is 294 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. The caloric content is 21 kcal/L.

    The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

  • CLINICAL PHARMACOLOGY

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) produces a metabolic alkalinizing effect. Acetate and gluconate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.

  • INDICATIONS AND USAGE

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is indicated as a source of water and electrolytes or as an alkalinizing agent.

  • CONTRAINDICATIONS

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is contraindicated in patients with a known hypersensitivity to the product. See WARNINGS.

  • WARNINGS

    Hypersensitivity Reactions

    Hypersensitivity and infusion reactions have been reported with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). See ADVERSE REACTIONS.

    Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia, chest pain, dyspnea and flushing. Institute appropriate therapeutic countermeasures as clinically indicated.

    Electrolyte Imbalances

    Fluid Overload

    Depending on the volume and rate of infusion, the intravenous administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can cause electrolyte disturbances such as overhydration and congested states, including pulmonary congestion and edema.

    Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor fluid balance, electrolyte concentrations, and acid base balance, as needed and especially during prolonged use.

    Hyponatremia

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.

    The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH) treated with high volume of hypotonic PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP).

    Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in hypervolemic or overhydrated patients. If use cannot be avoided, monitor serum sodium concentrations.

    Hypernatremia

    Hypernatremia may occur with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.

    Certain medications, such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention, see PRECAUTIONS.

    Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with, or at risk for, hypernatremia. If use cannot be avoided, monitor serum sodium concentrations.

    Hypermagnesemia

    Avoid solutions containing magnesium, including PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with or predisposed to hypermagnesemia, including patients with severe renal impairment and those patients receiving magnesium therapy (e.g., treatment of eclampsia and myasthenia gravis).

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is not indicated for the treatment of hypomagnesemia.

    Acidosis

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is not for use for the treatment of lactic acidosis or severe metabolic acidosis in patients with severe liver and/or renal impairment.

    Alkalosis

    Excess administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can result in metabolic alkalosis. Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with alkalosis or at risk for alkalosis.

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is not indicated for the treatment of hypochloremic hypokalemic alkalosis. Avoid use in patients with hypochloremic hypokalemic alkalosis.

    Hypocalcemia

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not-protein bound) calcium. Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with hypocalcemia.

    Hyperkalemia

    Potassium-containing solutions, including PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may increase the risk of hyperkalemia.

    Patient’s at increased risk of developing hyperkalemia include those:

    •
    With conditions predisposing to hyperkalemia and/or associated with increased sensitivity to potassium, such as patients with severe renal impairment, acute dehydration, extensive tissue injury or burns, certain cardiac disorders such as congestive heart failure.
    •
    Treated concurrently or recently with agents or products that cause or increase the risk of hyperkalemia (see PRECAUTIONS).

    Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with, or at risk for hyperkalemia If use cannot be avoided, monitor serum potassium concentrations.

    Although PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) has a potassium concentration similar to the concentration in plasma, it is insufficient to produce a useful effect in case of severe potassium deficiency; therefore, it is not indicated for correction of severe potassium deficiency.

  • PRECAUTIONS

    Patients with Renal Impairment

    In patients with renal impairment, administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may result in sodium and/or potassium or magnesium retention (see WARNINGS). Avoid PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with severe renal impairment or conditions that may cause sodium and/or potassium retention or magnesium retention, fluid overload, or edema. If use cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.

    Drug Interactions

    Other Products that Affect Fluid and/or Electrolyte Balance

    Administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance.

    Other Drugs that Increase the Risk of Hyponatremia

    Administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia.

    Avoid use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be avoided, monitor serum sodium concentrations.

    Lithium

    Renal clearance of lithium may be increased during administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). Monitor serum lithium concentrations during concomitant use.

    Other Products that Increase the Risk of Hyperkalemia

    Because of its potassium content, avoid use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations.

    Drugs with pH Dependent Renal Elimination

    Due to its alkalinizing effect (formation of bicarbonate), PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may interfere with the elimination of drugs with pH dependent renal elimination. Renal clearance of acidic drugs may be increased. Renal clearance of alkaline drugs may be decreased.

    Drug/Laboratory Test Interactions

    There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving Baxter gluconate containing PLASMA-LYTE solutions. These patients were subsequently found to be free of Aspergillus infection. Therefore, positive test results for this test in patients receiving Baxter gluconate containing PLASMA-LYTE solutions should be interpreted cautiously and confirmed by other diagnostic methods.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

    Pregnancy

    Teratogenic Effects

    Animal reproduction studies have not been conducted with PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP). It is also not known whether PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    It is not known where this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is administered to a nursing mother.

    Pediatric Use

    The use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in pediatric patients is based on clinical practice.

    Geriatric Use

    Geriatric patients are at increased risk of developing electrolyte imbalances. PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Consider monitoring renal function in elderly patients

  • ADVERSE REACTIONS

    Post-marketing Adverse Reactions

    The following adverse reactions associated with the use of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) were identified in clinical trials or postmarketing reports. Because postmarketing reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.

    Hypersensitivity and Infusion Reactions: tachycardia, palpitations, chest pain, chest discomfort, dyspnea, flushing, hyperemia, asthenia, feeling abnormal, piloerection, edema peripheral, pyrexia, hypotension, wheezing, urticaria, cold sweat, chills.

    General Disorders and Administration Site Conditions: infusion site pain, burning sensation.

    Metabolism and nutrition disorders: hyperkalemia, hyponatremia.

    Nervous System Disorders: hyponatremic encephalopathy.

    Overdose

    Excessive administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) can cause:

    •
    fluid overload with a risk of edema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired.
    •
    hypernatremia and hyperkalemia, especially in patients with severe renal impairment.
    •
    hypermagnesemia. See WARNINGS and ADVERSE REACTIONS
    •
    metabolic alkalosis with or without hypokalemia and decreased ionized serum calcium and magnesium concentrations.

    When assessing an overdose, any additives in the solution must also be considered.

    The effects of an overdose may require immediate medical attention and treatment.

    Interventions include discontinuation of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP), dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).

  • DOSAGE AND ADMINISTRATION

    Important Administration Instructions

    •
    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is intended for intravenous administration using sterile equipment.
    •
    Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
    •
    Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
    •
    Use a dedicated line without any connections to avoid air embolism.
    •
    Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container.
    •
    Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged.
    •
    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) is compatible with blood or blood components. It may be administered prior to or following the infusion of blood through the same administration set (i.e., as a priming solution), added to or infused concurrently with blood components, or used as a diluent in the transfusion of packed erythrocytes. PLASMA-LYTE 148 Injection and 0.9% Sodium Chloride Injection, USP are equally compatible with blood or blood components.

    Dosing Information

    The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.

    Introduction of Additives

    Additives may be incompatible.

    Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available.

    If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any unused portion.

  • HOW SUPPLIED

    PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below:

    CodeSize
    (mL)    		NDC

    2B2534

    1000

    NDC 0338-0179-04

    2B2533

    500

    NDC 0338-0179-03

    Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.

  • DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINER

    For Information on Risk of Air Embolism – see PRECAUTIONS

    To Open

    Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.

    Preparation for Administration

    1.
    Suspend container from eyelet support.
    2.
    Remove protector from outlet port at bottom of container.
    3.
    Attach administration set. Refer to complete directions accompanying set.

    To Add Medication

    To add medication before solution administration

    1.
    Prepare medication site.
    2.
    Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
    3.
    Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

    To add medication during solution administration

    1.
    Close clamp on the set.
    2.
    Prepare medication site.
    3.
    Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
    4.
    Remove container from IV pole and/or turn to an upright position.
    5.
    Evacuate both ports by squeezing them while container is in the upright position.
    6.
    Mix solution and medication thoroughly.
    7.
    Return container to in use position and continue administration.
  • SPL UNCLASSIFIED SECTION

    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA

    Printed in USA

     
    07-19-00-1558

    Rev. August 2019

    Baxter, Plasma-Lyte, Viaflex, and PL 146 are trademarks of Baxter International Inc.

  • PACKAGE LABEL - PRINCIPAL DISPLAY PANEL

    Package Label - Container 500 mL

    500 mL Container Label

    500 mL Container Label

    2B2533

    NDC 0338-0179-03

    PLASMA-LYTE 148
    Injection

    (Multiple Electrolytes Injection
    Type 1 USP)

    500 mL

    EACH 100 mL CONTAINS 526 mg SODIUM CHLORIDE USP 502 mg
    SODIUM GLUCONATE USP 368 mg SODIUM ACETATE TRIHYDRATE
    USP 37 mg POTASSIUM CHLORIDE USP 30 mg MAGNESIUM
    CHLORIDE USP pH ADJUSTED WITH HYDROCHLORIC ACID pH 5.5
    (4.0 TO 8.0) mEq/L SODIUM 140 POTASSIUM 5 MAGNESIUM 3
    CHLORIDE 98 ACETATE 27 GLUCONATE 23 OSMOLARITY 294
    mOsmol/L (CALC) STERILE NONPYROGENIC SINGLE DOSE CONTAINER
    ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH PHARMACIST IF
    AVAILABLE WHEN INTRODUCING ADDITIVES USE ASEPTIC TECHNIQUE
    MIX THOROUGHLY DO NOT STORE DOSAGE INTRAVENOUSLY AS
    DIRECTED BY A PHYSICIAN SEE DIRECTIONS CAUTIONS SQUEEZE AND
    INSPECT INNER BAG WHICH MAINTAINS PRODUCT STERILITY DISCARD IF
    LEAKS ARE FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO
    NOT USE UNLESS SOLUTION IS CLEAR RX ONLY STORE UNIT IN
    MOISTURE BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F)
    UNTIL READY TO USE AVOID EXCESSIVE HEAT SEE INSERT

    VIAFLEX CONTAINER
    PL 146 PLASTIC

    FOR PRODUCT INFORMATION
    1-800-933-0303

    BAXTER PLASMA-LYTE VIAFLEX
    AND PL 146 ARE TRADEMARKS OF
    BAXTER INTERNATIONAL INC

    Baxter logo
    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA
    MADE IN USA

    Package Label - Container 1000 mL

    1000 mL Container Label

    1000 mL Container Label

    LOT

    EXP

    2B2534

    NDC 0338-0179-04

    Plasma-Lyte
    148 Injection

    (Multiple Electrolytes
    Injection Type 1 USP)

    1000 mL

    EACH 100 mL CONTAINS 526 mg SODIUM CHLORIDE USP 502
    mg SODIUM GLUCONATE USP 368 mg SODIUM ACETATE
    TRIHYDRATE USP 37 mg POTASSIUM CHLORIDE USP 30 mg
    MAGNESIUM CHLORIDE USP pH ADJUSTED WITH HYDROCHLORIC
    ACID pH 5.5 (4.0 TO 8.0) mEq/L SODIUM 140 POTASSIUM 5
    MAGNESIUM 3 CHLORIDE 98 ACETATE 27 GLUCONATE 23
    OSMOLARITY 294 mOsmol/L (CALC) STERILE NONPYROGENIC
    SINGLE DOSE CONTAINER ADDITIVES MAY BE INCOMPATIBLE
    CONSULT WITH PHARMACIST IF AVAILABLE WHEN INTRODUCING
    ADDITIVES USE ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT
    STORE DOSAGE INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN
    SEE DIRECTIONS CAUTIONS SQUEEZE AND INSPECT INNER BAG
    WHICH MAINTAINS PRODUCT STERILITY DISCARD IF LEAKS ARE
    FOUND MUST NOT BE USED IN SERIES CONNECTIONS DO NOT USE
    UNLESS SOLUTION IS CLEAR RX ONLY STORE UNIT IN MOISTURE
    BARRIER OVERWRAP AT ROOM TEMPERATURE (25°C/77°F) UNTIL
    READY TO USE AVOID EXCESSIVE HEAT SEE INSERT

    VIAFLEX CONTAINER PL 146 PLASTIC

    BAXTER PLASMA-LYTE VIAFLEX AND PL 146 ARE
    TRADEMARKS OF BAXTER INTERNATIONAL INC

    FOR PRODUCT INFORMATION 1-800-933-0303

    Baxter logo
    BAXTER HEALTHCARE CORPORATION
    DEERFIELD IL 60015 USA
    MADE IN USA

  • INGREDIENTS AND APPEARANCE
    PLASMA-LYTE 148 
    sodium chloride, sodium gluconate, sodium acetate, potassium chloride, and magnesium chloride injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0338-0179
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698) SODIUM CHLORIDE526 mg  in 100 mL
    SODIUM GLUCONATE (UNII: R6Q3791S76) (GLUCONIC ACID - UNII:R4R8J0Q44B, SODIUM CATION - UNII:LYR4M0NH37) SODIUM GLUCONATE502 mg  in 100 mL
    SODIUM ACETATE (UNII: 4550K0SC9B) (ACETATE ION - UNII:569DQM74SC, SODIUM CATION - UNII:LYR4M0NH37) SODIUM ACETATE368 mg  in 100 mL
    POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32ZN48698) POTASSIUM CHLORIDE37 mg  in 100 mL
    MAGNESIUM CHLORIDE (UNII: 02F3473H9O) (MAGNESIUM CATION - UNII:T6V3LHY838, CHLORIDE ION - UNII:Q32ZN48698) MAGNESIUM CHLORIDE30 mg  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0338-0179-03500 mL in 1 BAG; Type 0: Not a Combination Product02/02/1979
    2NDC:0338-0179-041000 mL in 1 BAG; Type 0: Not a Combination Product02/02/1979
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01737802/02/1979
    Labeler - Baxter Healthcare Corporation (005083209)
    Registrant - Baxter Healthcare Corporation (005083209)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation059140764ANALYSIS(0338-0179) , MANUFACTURE(0338-0179) , LABEL(0338-0179) , PACK(0338-0179) , STERILIZE(0338-0179)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation194684502ANALYSIS(0338-0179)
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials

More Info on this Drug

Get Label RSS Feed, View NDC Code(s)NEW!